Victory Capital Management
CTMX icon

Victory Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Victory Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$59.2K Buy
21,747
+2,441
+13% +$8.14K ﹤0.01% 2418
2026
Q2 		$72.4K Buy
19,306
+4,145
+27% +$15.8K ﹤0.01% 2359
2026
Q1 		$71.3K Buy
15,161
+439
+3% +$2.23K ﹤0.01% 2294
2025
Q4 		$62.7K Buy
14,722
+601
+4% +$2.28K ﹤0.01% 2312
2025
Q3 		$45K Buy
14,121
+1,686
+14% +$3.8K ﹤0.01% 2349
2025
Q2 		$28.2K Buy
+12,435
New +$20K ﹤0.01% 2420
2021
Q4 		– Sell
-3,269,112
Closed -$16.6M – 2790
2021
Q3 		$16.6M Buy
3,269,112
+400,126
+14% +$2.14M 0.02% 954
2021
Q2 		$18.2M Buy
2,868,986
+100,104
+4% +$779K 0.02% 935
2021
Q1 		$21.4M Buy
2,768,882
+451,485
+19% +$3.57M 0.02% 885
2020
Q4 		$15.2M Sell
2,317,397
-110,409
-5% -$789K 0.02% 983
2020
Q3 		$16.1M Buy
2,427,806
+150,846
+7% +$1.12M 0.02% 890
2020
Q2 		$19M Sell
2,276,960
-495,466
-18% -$4.6M 0.03% 805
2020
Q1 		$21.3M Sell
2,772,426
-41,025
-1% -$286K 0.04% 634
2019
Q4 		$23.4M Buy
2,813,451
+191,329
+7% +$1.29M 0.03% 769
2019
Q3 		$19.4M Buy
2,622,122
+636,132
+32% +$6.28M 0.02% 804
2019
Q2 		$22.3M Buy
1,985,990
+330,460
+20% +$3.46M 0.04% 576
2019
Q1 		$17.8M Buy
1,655,530
+735,320
+80% +$10.9M 0.04% 596
2018
Q4 		$13.9M Buy
920,210
+29,810
+3% +$442K 0.03% 640
2018
Q3 		$16.5M Buy
890,400
+773,080
+659% +$17.6M 0.03% 656
2018
Q2 		$2.68M Sell
117,320
-6,710
-5% -$171K 0.01% 1010
2018
Q1 		$3.53M Buy
+124,030
New +$3.54M 0.01% 903

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Victory Capital Management's CTMX Position: Q3 2026 in Review

Victory Capital Management increased its CytomX Therapeutics (CTMX) stake by 13% in Q3 2026, buying an estimated $8.14K and bringing the position to 21,747 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2418.

Victory Capital Management first reported a position in CTMX in Q1 2018 and has held it in 21 quarters since. The position peaked at $23.4M in Q4 2019. 128 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Victory Capital Management held 21,747 shares of CytomX Therapeutics worth $59.2K as of Q3 2026.
  • Victory Capital Management bought 2,441 CytomX Therapeutics shares in Q3 2026, an estimated $8.14K.
  • CytomX Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #2418 holding.
  • Victory Capital Management first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 21 quarters since.
  • Victory Capital Management's CytomX Therapeutics position peaked at $23.4M in Q4 2019.
  • 128 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.